Comparative Pharmacology
Head-to-head clinical analysis: DIPRIVAN versus FLUOTHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPRIVAN versus FLUOTHANE.
DIPRIVAN vs FLUOTHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
None Documented
None Documented
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
Category C
Category C
General Anesthetic
General Anesthetic